Protagonist Therapeutics Inc ((PTGX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Protagonist Therapeutics Inc. has recently completed a Phase 2 clinical study titled ‘A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients With Phlebotomy-Requiring Polycythemia Vera.’ The study aimed to evaluate the safety and preliminary efficacy of PTG-300, a hepcidin mimetic, in managing polycythemia vera, a condition requiring frequent phlebotomy. This study is significant as it explores a potential new treatment pathway for patients with this chronic condition.
The intervention tested in this study is PTG-300, a drug designed to mimic hepcidin, which is intended to reduce the need for phlebotomy in patients with polycythemia vera by maintaining hematocrit levels below 45%.
The study was interventional and randomized, with a parallel assignment model. It included a 28-week open-label dose escalation phase, a 12-week blinded randomized withdrawal phase, and an open-label extension of up to three years. The study employed triple masking during the withdrawal phase to ensure unbiased results.
The study began on October 1, 2019, and was completed as of the last update on August 4, 2025. These dates are crucial as they mark the timeline for data collection and analysis, impacting the timing of potential market entry for PTG-300.
The completion of this study could positively influence Protagonist Therapeutics’ stock performance, as successful results may lead to a new treatment option for polycythemia vera, potentially increasing market share. Investors should watch for competitor developments in the same therapeutic area, as advancements could affect market dynamics.
The study is now completed, with further details available on the ClinicalTrials portal.